Hsbc Holdings PLC Buys Shares of 12,417 Humacyte, Inc. (NASDAQ:HUMA)

Hsbc Holdings PLC purchased a new stake in Humacyte, Inc. (NASDAQ:HUMA) during the fourth quarter, according to its most recent filing with the SEC. The firm purchased 12,417 shares of the company’s stock, valued at approximately $62,000.

A number of other hedge funds have also modified their holdings of the company. First Trust Advisors LP acquired a new stake in shares of Humacyte in the 4th quarter valued at approximately $1,720,000. Rather & Kittrell Inc. acquired a new stake in shares of Humacyte in the 4th quarter valued at approximately $88,000. Rossby Financial LCC acquired a new stake in shares of Humacyte in the 4th quarter valued at approximately $126,000. Walleye Capital LLC acquired a new stake in shares of Humacyte in the 4th quarter valued at approximately $539,000. Finally, XTX Topco Ltd raised its position in shares of Humacyte by 29.0% in the 4th quarter. XTX Topco Ltd now owns 43,929 shares of the company’s stock valued at $222,000 after acquiring an additional 9,880 shares during the period. 44.71% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Humacyte

In other Humacyte news, Director Kathleen Sebelius purchased 50,000 shares of the firm’s stock in a transaction dated Tuesday, April 8th. The stock was bought at an average cost of $1.32 per share, with a total value of $66,000.00. Following the purchase, the director now directly owns 91,207 shares of the company’s stock, valued at $120,393.24. The trade was a 121.34% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Dale A. Sander purchased 20,000 shares of the firm’s stock in a transaction dated Thursday, April 10th. The shares were acquired at an average cost of $1.53 per share, with a total value of $30,600.00. Following the completion of the purchase, the chief financial officer now directly owns 40,600 shares in the company, valued at approximately $62,118. This represents a 97.09% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired 83,993 shares of company stock valued at $118,224 in the last ninety days. 11.20% of the stock is currently owned by corporate insiders.

Humacyte Stock Performance

Shares of HUMA stock opened at $1.32 on Tuesday. The company has a market capitalization of $204.76 million, a P/E ratio of -0.99 and a beta of 1.64. The company’s 50 day moving average price is $1.91 and its two-hundred day moving average price is $3.56. Humacyte, Inc. has a 52 week low of $1.15 and a 52 week high of $9.97.

Humacyte (NASDAQ:HUMA) last issued its quarterly earnings results on Friday, March 28th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.07. The business had revenue of $7.23 million for the quarter, compared to the consensus estimate of $0.64 million. Analysts forecast that Humacyte, Inc. will post -1.27 earnings per share for the current year.

Wall Street Analysts Forecast Growth

HUMA has been the topic of a number of analyst reports. D. Boral Capital reiterated a “buy” rating and issued a $25.00 price target on shares of Humacyte in a research report on Wednesday, March 26th. Benchmark restated a “buy” rating on shares of Humacyte in a report on Thursday, February 27th. Finally, HC Wainwright restated a “buy” rating and set a $15.00 target price on shares of Humacyte in a report on Wednesday, March 12th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $13.71.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.